C I Hatleberg1, L Ryom1, A d'Arminio Monforte2, E Fontas3, P Reiss4, O Kirk1, W El-Sadr5, A Phillips6, S de Wit7, F Dabis8, R Weber9, M Law10, J D Lundgren1, C Sabin6. 1. Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases Section 2100, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 2. Department of Health Sciences, Clinic of Infectious and Tropical Diseases, San Paolo University Hospital, Milan, Italy. 3. Department of Public Health, Nice University Hospital, Nice, France. 4. Academic Medical Center, Department of Global Health and Division of Infectious Diseases, HIV Monitoring Foundation, University of Amsterdam, Amsterdam, the Netherlands. 5. International Center for AIDS Care and Treatment Programs (ICAP), Harlem Hospital, Columbia University, New York, NY, USA. 6. Insititute for Global Health, University College London, London, UK. 7. Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium. 8. Bordeaux Hospital University Centre (CHU) and INSERM U897, University of Bordeaux, Talence, France. 9. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 10. Kirby Institute, University of New South Wales, Sydney, Australia.
Abstract
OBJECTIVES: Previous studies have suggested that hypertension in HIV-positive individuals is associated primarily with traditional risk factors such as older age, diabetes and dyslipidaemia. However, controversy remains as to whether exposure to antiretroviral (ARV) drugs poses additional risk, and we investigated this question in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort. METHODS: The incidence of hypertension [systolic blood pressure (BP) > 140 and/or diastolic BP > 90 mmHg and/or initiation of antihypertensive treatment] was determined overall and in strata defined by demographic, metabolic and HIV-related factors, including cumulative exposure to each individual ARV drug. Predictors of hypertension were identified using uni- and multivariable Poisson regression models. RESULTS: Of 33 278 included persons, 7636 (22.9%) developed hypertension over 223 149 person-years (PY) [incidence rate: 3.42 (95% confidence interval (CI) 3.35-3.50) per 100 PY]. In univariable analyses, cumulative exposure to most ARV drugs was associated with an increased risk of hypertension. After adjustment for demographic, metabolic and HIV-related factors, only associations for nevirapine [rate ratio 1.07 (95% CI: 1.04-1.13) per 5 years] and indinavir/ritonavir [rate ratio 1.12 (95% CI: 1.04-1.20) per 5 years] remained statistically significant, although effects were small. The strongest independent predictors of hypertension were male gender, older age, black African ethnicity, diabetes, dyslipidaemia, use of lipid-lowering drugs, high body mass index (BMI), renal impairment and a low CD4 count. CONCLUSIONS: We did not find evidence for any strong independent association between exposure to any of the individual ARV drugs and the risk of hypertension. Findings provide reassurance that screening policies and preventative measures for hypertension in HIV-positive persons should follow algorithms used for the general population.
OBJECTIVES: Previous studies have suggested that hypertension in HIV-positive individuals is associated primarily with traditional risk factors such as older age, diabetes and dyslipidaemia. However, controversy remains as to whether exposure to antiretroviral (ARV) drugs poses additional risk, and we investigated this question in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort. METHODS: The incidence of hypertension [systolic blood pressure (BP) > 140 and/or diastolic BP > 90 mmHg and/or initiation of antihypertensive treatment] was determined overall and in strata defined by demographic, metabolic and HIV-related factors, including cumulative exposure to each individual ARV drug. Predictors of hypertension were identified using uni- and multivariable Poisson regression models. RESULTS: Of 33 278 included persons, 7636 (22.9%) developed hypertension over 223 149 person-years (PY) [incidence rate: 3.42 (95% confidence interval (CI) 3.35-3.50) per 100 PY]. In univariable analyses, cumulative exposure to most ARV drugs was associated with an increased risk of hypertension. After adjustment for demographic, metabolic and HIV-related factors, only associations for nevirapine [rate ratio 1.07 (95% CI: 1.04-1.13) per 5 years] and indinavir/ritonavir [rate ratio 1.12 (95% CI: 1.04-1.20) per 5 years] remained statistically significant, although effects were small. The strongest independent predictors of hypertension were male gender, older age, black African ethnicity, diabetes, dyslipidaemia, use of lipid-lowering drugs, high body mass index (BMI), renal impairment and a low CD4 count. CONCLUSIONS: We did not find evidence for any strong independent association between exposure to any of the individual ARV drugs and the risk of hypertension. Findings provide reassurance that screening policies and preventative measures for hypertension in HIV-positive persons should follow algorithms used for the general population.
Authors: Alan R Lifson; Jacqueline Neuhaus; Jose Ramon Arribas; Mary van den Berg-Wolf; Ann M Labriola; Timothy R H Read Journal: Am J Public Health Date: 2010-08-19 Impact factor: 9.308
Authors: Chidozie U Nduka; Saverio Stranges; Gerald S Bloomfield; Peter K Kimani; Godwin Achinge; Abraham O Malu; Olalekan A Uthman Journal: Int J Cardiol Date: 2016-06-27 Impact factor: 4.164
Authors: Carlos Jericó; Hernando Knobel; Milagro Montero; María L Sorli; Ana Guelar; Juan L Gimeno; Pere Saballs; Jose L López-Colomés; Juan Pedro-Botet Journal: Am J Hypertens Date: 2005-11 Impact factor: 2.689
Authors: Colette J Smith; Lene Ryom; Rainer Weber; Philippe Morlat; Christian Pradier; Peter Reiss; Justyna D Kowalska; Stephane de Wit; Matthew Law; Wafaa el Sadr; Ole Kirk; Nina Friis-Moller; Antonella d'Arminio Monforte; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: Lancet Date: 2014-07-19 Impact factor: 79.321
Authors: Virginia A Triant; Susan Regan; Hang Lee; Paul E Sax; James B Meigs; Steven K Grinspoon Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: Katherine Krauskopf; Mark L Van Natta; Ronald P Danis; Sapna Gangaputra; Lori Ackatz; Adrienne Addessi; Alex D Federman; Andrea D Branch; Curtis L Meinert; Douglas A Jabs Journal: J Int Assoc Provid AIDS Care Date: 2013 Sep-Oct
Authors: Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood Journal: Eur Heart J Date: 2013-06-14 Impact factor: 29.983
Authors: Tiffany E Gooden; Mike Gardner; Jingya Wang; Kate Jolly; Deirdre A Lane; Laura A Benjamin; Henry C Mwandumba; Vanessa Kandoole; Isaac B Lwanga; Stephen Taylor; Semira Manaseki-Holland; Gregory Y H Lip; Krishnarajah Nirantharakumar; G Neil Thomas Journal: J Infect Dis Date: 2022-04-19 Impact factor: 7.759
Authors: Olga Tymejczyk; Marie Marcelle Deschamps; Vanessa Rouzier; Margaret L McNairy; Robert N Peck; Line Malha; Youry Macius; Daniel W Fitzgerald; Jean W Pape; Denis Nash Journal: J Clin Hypertens (Greenwich) Date: 2022-02-07 Impact factor: 3.738
Authors: Urgent Tsuro; Kelechi E Oladimeji; Guillermo-Alfredo Pulido-Estrada; Teke R Apalata Journal: Int J Environ Res Public Health Date: 2022-09-06 Impact factor: 4.614
Authors: Dathan M Byonanebye; Mark N Polizzotto; Bastian Neesgaard; Mario Sarcletti; Raimonda Matulionyte; Dominique L Braun; Antonella Castagna; Stéphane de Wit; Ferdinand Wit; Eric Fontas; Jörg Janne Vehreschild; Jan Vesterbacka; Lauren Greenberg; Camilla Hatleberg; Harmony Garges; Joel Gallant; Alain Volny Anne; Angela Öllinger; Iwona Mozer-Lisewska; Bernard Surial; Vincenzo Spagnuolo; Coca Necsoi; Marc van der Valk; Amanda Mocroft; Matthew Law; Lene Ryom; Kathy Petoumenos Journal: HIV Med Date: 2022-03-01 Impact factor: 3.094